ERBB2 and breast cancer: Dysregulation of the PI3K/AKT/mTOR pathway by activating mutations in PIK3CA and AKT1 and/or inactivating PTEN are most frequently observed in HR+/HER2- BCs, which are found to be mutually exclusive (GENIE breast cancer cohort, Supplemental Figure S1).